In Silico Development of SARS-CoV-2 Non-covalent Mpro Inhibitors: A Review DOI Open Access

Islam Alagawani,

Feng Wang

Опубликована: Сен. 2, 2024

Coronaviruses (CoVs) have recently emerged as significant causes of respiratory disease outbreaks. The novel coronavirus pneumonia 2019, known COVID-19, are highly infectious and triggered by severe acute syndrome 2 (SARS-CoV-2). Understanding virus-host interactions molecular targets in host cell death signalling is crucial for treatment development. Small natural compounds like celastrol curcumin, acting proteasome inhibitors, can potentially modify NF-κB treating SARS-CoV-2 infections. Various constituents, including alkaloids, flavonoids, terpenoids, diarylheptanoids, anthraquinones, inhibit viral infection, progression, amplification coronaviruses. Derived from medicinal herbs, these possess anti-inflammatory antiviral properties, impacting the life cycle, entry, replication, assembly, release COVID-19 virions. This review focuses on development small molecules non-covalent inhibitors targeting Main Protease (Mpro, also called 3CLpro) enzyme SARS-CoV-2. It highlights design using dynamics (MD) studies computational methods further improvements Mpro inhibitor design. in-silico approach, which pivotal this process, provides an accelerated virtual avenue exploring developing potential representing latest advancements drug

Язык: Английский

The Design, Synthesis and Mechanism of Action of Paxlovid, a Protease Inhibitor Drug Combination for the Treatment of COVID-19 DOI Creative Commons
Miklós Bege, Anikó Borbás

Pharmaceutics, Год журнала: 2024, Номер 16(2), С. 217 - 217

Опубликована: Фев. 2, 2024

The COVID-19 pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has presented an enormous challenge to health care systems and medicine. As a result of global research efforts aimed at preventing effectively treating SARS-CoV-2 infection, vaccines with fundamentally new mechanisms action some small-molecule antiviral drugs targeting key proteins in the viral cycle have been developed. most effective drug approved date for treatment is PaxlovidTM, which combination two protease inhibitors, nirmatrelvir ritonavir. Nirmatrelvir reversible covalent peptidomimetic inhibitor main (Mpro) SARS-CoV-2, enzyme plays crucial role reproduction. In this combination, ritonavir serves as pharmacokinetic enhancer, it irreversibly inhibits cytochrome CYP3A4 responsible rapid metabolism nirmatrelvir, thereby increasing half-life bioavailability nirmatrelvir. tutorial review, we summarize development pharmaceutical chemistry aspects Paxlovid, covering evolution warhead design, synthesis mechanism well its inhibition mechanism. efficacy Paxlovid novel virus mutants also overviewed.

Язык: Английский

Процитировано

14

Non-peptidic inhibitors targeting SARS-CoV-2 main protease: A review DOI

Ya-Qi Xiao,

Jiao Long, Shuang‐Shuang Zhang

и другие.

Bioorganic Chemistry, Год журнала: 2024, Номер 147, С. 107380 - 107380

Опубликована: Апрель 16, 2024

Язык: Английский

Процитировано

7

Exploring covalent inhibitors of SARS-CoV-2 main protease: from peptidomimetics to novel scaffolds DOI Creative Commons
Noor Atatreh, Radwa E. Mahgoub, Mohammad A. Ghattas

и другие.

Journal of Enzyme Inhibition and Medicinal Chemistry, Год журнала: 2025, Номер 40(1)

Опубликована: Фев. 6, 2025

Peptidomimetic inhibitors mimic natural peptide substrates, employing electrophilic warheads to covalently interact with the catalytic Cys145 of Mpro. Examples include aldehydes, α-ketoamides, and aza-peptides, discussions on their mechanisms action, potency, structural insights. Non-peptidomimetic utilise diverse scaffolds mechanisms, achieving covalent modification

Язык: Английский

Процитировано

0

Applications of Molecular Docking Studies in SARS-CoV-2 Targeted Drug Discovery and the Gains Achieved through Molecular Docking DOI Creative Commons

Merve Yildirim,

İsmail Çeli̇k

Biomedical engineering, Год журнала: 2024, Номер unknown

Опубликована: Апрель 29, 2024

In this chapter, we delve into the pivotal role of molecular docking in realm computational biology and chemistry, focusing specifically on its application drug discovery targeting SARS-CoV-2. Molecular docking, a critical technique, has played significant predicting interactions bindings molecules, particularly concerning SARS-CoV-2’s main protease RNA polymerase. This chapter highlights synergy between virtual screening, emphasizing expedited identification evaluation potential candidates against Through comprehensive discussion, aim to provide nuanced understanding rapid advancements for SARS-CoV-2, accentuating indispensable value tools methods contemporary therapeutic development.

Язык: Английский

Процитировано

1

In Silico Development of SARS-CoV-2 Non-covalent Mpro Inhibitors: A Review DOI Open Access

Islam Alagawani,

Feng Wang

Опубликована: Сен. 2, 2024

Coronaviruses (CoVs) have recently emerged as significant causes of respiratory disease outbreaks. The novel coronavirus pneumonia 2019, known COVID-19, are highly infectious and triggered by severe acute syndrome 2 (SARS-CoV-2). Understanding virus-host interactions molecular targets in host cell death signalling is crucial for treatment development. Small natural compounds like celastrol curcumin, acting proteasome inhibitors, can potentially modify NF-κB treating SARS-CoV-2 infections. Various constituents, including alkaloids, flavonoids, terpenoids, diarylheptanoids, anthraquinones, inhibit viral infection, progression, amplification coronaviruses. Derived from medicinal herbs, these possess anti-inflammatory antiviral properties, impacting the life cycle, entry, replication, assembly, release COVID-19 virions. This review focuses on development small molecules non-covalent inhibitors targeting Main Protease (Mpro, also called 3CLpro) enzyme SARS-CoV-2. It highlights design using dynamics (MD) studies computational methods further improvements Mpro inhibitor design. in-silico approach, which pivotal this process, provides an accelerated virtual avenue exploring developing potential representing latest advancements drug

Язык: Английский

Процитировано

1